Palabras clave
Cómo citar
Resumen
Los eventos tromboembólicos ocupan los primeros lugares de morbimortalidad prevenibles en los pacientes hospitalizados, así como también representan un aumento en la carga financiera y asistencial en los sistemas de salud. La aplicación de tromboprofilaxis en pacientes de manejo médico se implementa de forma subóptima debido al temor a presentar sangrado o por subestimación del riesgo de eventos trombóticos. La aplicación de herramientas para la estimación del riesgo de eventos tromboembólicos se plantea como una ayuda en la toma de la decisión de iniciar o no estrategias de tromboprofilaxis en pacientes hospitalizados con el objetivo de disminuir la incidencia y prevalencia de estos eventos, así como la morbimortalidad asociada.
Palabras clave: trombosis venosa, tromboembolismo pulmonar, profilaxis, prevención.
Citas
Ye F, Bell LN, Mazza J, Lee A, Yale SH. Variation in Definitions of Immobility in Pharmacological Thromboprophylaxis Clinical Trials in Medical Inpatients: A Systematic Review. Clin Appl Thromb Hemost. 2018 Jan;24(1):13-21.
Heit JA, Ashrani A, Crusan DJ, McBane RD, Petterson TM, Bailey KR. Reasons for the persistent incidence of venous thromboembolism. Thromb Haemost. 2017 Jan 26;117(2):390-400.
Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J et al. The Worcester Venous Thromboembolism study: a population-based study of the clinicalepidemiology of venous thromboembolism. J Gen Intern Med. 2006 Jul;21(7):722-7.
Douketis JD. Prevention of venous thromboembolism in hospitalized medical patients: addressing some practical questions: Curr Opin Pulm Med. 2008 Sep;14(5):381-8.
Marušič AP, Locatelli I, Mrhar A, Caprnda M, Gaspar L, Adamek M et al. Influence of Prescribed Blood Products on the Incidence of Deep Vein Thrombosis and Pulmonary Embolism in Surgical Patients. Clin Appl Thromb. 2017 Nov;23(8):938-42.
Veeranki SP, Xiao Z, Levorsen A, Sinha M, Shah BR. Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients. Am J Cardiovasc Drugs. 2021 Jul;21(4):443-452.
Darzi AJ, Repp AB, Spencer FA, Morsi RZ, Charide R, Etxeandia-Ikobaltzeta I, Bauer KA, Burnett AE, Cushman M, Dentali F, Kahn SR, Rezende SM, Zakai NA, Agarwal A, Karam SG, Lotfi T, Wiercioch W, Waziry R, Iorio A, Akl EA, Schünemann HJ. Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews. Blood Adv. 2020 Oct 13;4(19):4929-4944.
Cohen AT, Tapson VF, Bergmann J-F, Goldhaber SZ, Kakkar AK, Deslandes B et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet Lond Engl. 2008 Feb;371(9610):387-94.
Mahan CE, Fisher MD, Mills RM, Fields LE, Stephenson JJ, Fu A-C et al. Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population. Thromb Res. 2013 Nov;132(5):520-6.
Flanders SA, Greene MT, Grant P, Kaatz S, Paje D, Lee B et al. Hospital performance for pharmacologicvenous thromboembolism prophylaxis and rate of venous thromboembolism : a cohort study. JAMA Intern Med. 2014 Oct;174(10):1577-84.
Spyropoulos AC, Anderson FA, FitzGerald G, Decousus H, Pini M, Chong BH et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011 Sep;140(3):706-14.
Spyropoulos AC, Raskob GE. New paradigms in venous thromboprophylaxis of medically ill patients. Thromb Haemost. 2017;117(09):1662-70.
MacDougall K, Spyropoulos AC. New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients. J Clin Med. 2020 Apr 2;9(4):1002.
Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med. 1982 Jul;10(7):448-50.
Nicolaides AN, Breddin HK, Fareed J, Goldhaber S, Haas S, Hull R et al. Prevention of venous thromboembolism. International Consensus Statement.
Guidelines compiled in accordance with the scientificevidence. Int Angiol J Int Union Angiol. 2001 Mar;20(1):1-37.
Enders JM, Burke JM, Dobesh PP. Prevention of venous thromboembolism in acute medical illness. Pharmacotherapy. 2002 Dic;22(12):1564-78.
Cohen AT, Edmondson RA, Phillips MJ, Ward VP, & Kakkar VV. The changing pattern of venous thromboembolic disease. Haemostasis. 1996 Abr;26(2):65-71.
Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999 Sep 9;341(11):793-800.
Leizorovicz A, Cohen AT, Turpie AGG, Olsson C-G, Vaitkus PT, Goldhaber SZ et al. Randomized, placebocontrolled trial of dalteparin for the prevention ofvenous thromboembolism in acutely ill medical patients. Circulation. 2004 Ago;110(7):874-9.
Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006 Feb;332(7537):325-9.
Dentali F, Douketis JD, Gianni M, Lim W et Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007 Feb;146(4):278-88.
Liew AYL, Piran S, Eikelboom JW et Douketis JD.Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials. J Thromb Thrombolysis. 2017 Abr;43(3):291-301.
Stuck A, Spirk D, Schaudt J, & Kucher N. Risk assessment models for venous thromboembolism in acutely ill medical patients: A systematic review. Thromb Haemost. 2017;117(04):801-8.
Kucher N, Koo S, Quiroz R, Cooper JM, Paterno MD, Soukonnikov B, Goldhaber SZ. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005 Mar 10;352(10):969-77.
Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost JTH. 2010 Nov;8(11):2450-7.
Lester W, Freemantle N, Begaj I, Ray D, Wood J et Pagano D. Fatal venous thromboembolism associated with hospital admission: a cohort study to assess theimpact of a national risk assessment target. Heart Br Card Soc. 2013 Dic;99(23):1734-9.
Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical PreventionRegistry on Venous Thromboembolism. Chest. 2007 Sep;132(3):936-45.
Nendaz M, Spirk D, Kucher N, Aujesky D, Hayoz D, Beer JH et al. Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit ASsessment of Thromboembolic RIsk and Prophylaxis for Medical PATients in SwitzErland (ESTIMATE). Thromb Haemost. 2014 Mar;111(3):531-8.
Amin A, Spyropoulos AC, Dobesh P, Shorr A, Hussein M, Mozaffari E et al. Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). J Thromb Thrombolysis. 2010 Abr;29(3):326-39.
Decousus H, Tapson VF, Bergmann J-F, Chong BH, Froehlich JB, Kakkar AK et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011 Ene;139(1):69-79.
Rosenberg DJ, Press A, Fishbein J, Lesser M, McCullagh L, McGinn T et al. External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients. Thromb Haemost. 2016 30;116(3):530-6.
Weitz JI, Fredenburgh JC et Eikelboom JW. A Test inContext: D-Dimer. Journal of the American College of Cardiology. 2017;70(19):2411–2420.
Favresse J, Lippi G, Roy P-M, Chatelain B, Jacqmin H, ten Cate H et Mullier F. D-dimer: Preanalytical, analytical, postanalytical variables, and clinical applications. Critical Reviews in Clinical Laboratory Sciences. 2018;55(8):548–577.
Legnani C, Palareti G, Cosmi B, Cini M, Tosetto A et Tripodi A. Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study. Haematologica. 2008;93(6):900–907.
Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T et Lim W. Systematic Review: d-Dimer to Predict Recurrent Disease after Stopping Anticoagulant Therapy for Unprovoked Venous Thromboembolism. Annals of Internal Medicine. 2008 149(7):481.
Nagler M, ten Cate H, Prins MH et ten Cate-Hoek AJ. Risk factors for recurrence in deep vein thrombosis patients following a tailored anticoagulant treatment incorporating residual vein obstruction. Research and Practice in Thrombosis and Haemostasis. 2018;2(2):299–309.
Ageno W, Squizzato A, Wells PS, Büller HR et Johnson G. The diagnosis of symptomatic recurrent pulmonary embolism and deep vein thrombosis: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2013;11(8):1597–1602
Baglin T, Luddington R, Brown K et Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. The Lancet. 2003;362(9383):523–526.
Todo el material publicado en la revista Hematología (versión electrónica y versión impresa), será cedido a la Sociedad Argentina de Hematología. De conformidad con la ley de derecho de autor (ley 11723) se les enviara a los autores de cada trabajo aceptado formulario de cesión de derechos de autor que deberá ser firmado por todos los autores antes de la publicación. Los autores deberán retener una copia del original pues la revista, no acepta responsabilidad por daños o pérdidas del material enviado. Los autores deberán remitir una versión electrónica al correo: revista@sah.org.ar